AOAnne Claire B. van Orten-Luiten

Anne Claire B. van Orten-Luiten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne Claire B. van Orten-Luiten has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A drug-based model to predict hyponatremia in outpatients of a geriatric clinic

    by Anne Claire B. van Orten-Luiten, Elske M. Brouwer-Brolsma, André Janse, Renger F. Witkamp

    Purpose: Chronic hyponatremia in older people is associated with adverse outcomes including gait disturbances, falls, osteoporosis, fractures, cognitive impairment, and cardiovascular disease. Diagnosis in outpatient settings is challenging due to the non-specific nature of its symptoms. While hyponatremia is well-studied in hospitalized patients, little research has focused on outpatient settings. This study aimed to develop a drug-based model to non-invasively predict hyponatremia in older adults attending a geriatric outpatient clinic. Methods: Cross-sectional data from 2181 outpatients aged ≥ 55 were analysed using logistic regression. Polypharmacy, 27 specific drug groups, sex, age, and BMI were considered as potential risk factors. Predictors were selected using stepwise backward logistic regression for the complex model and LASSO regression for the simple model. Internal validation was performed through bootstrapping, and model performance was evaluated by constructing a receiver operating characteristic (ROC) curve. Results: The prevalence of hyponatremia was 10.5%, with higher occurrence in women. The complex model identified predictors including sex, age, BMI, polypharmacy, and 11 drug groups, achieving an area under the curve (AUC) of 0.75, [95% CI 0.72–0.79], indicating a reasonably good ability to distinguish between hypo- and normonatremia. The simple model, including only polypharmacy, had limited predictive performance (AUC = 0.64 [95% CI 0.60–0.68]). Conclusion: The complex, drug-based model predicts hyponatremia risk in outpatients of a geriatric clinic. Timely recognition may prevent inappropriate treatments for undiagnosed cases and associated harms. The model merits further development for clinical use.


  • Open Access

    Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing

    by Anne-Claire B. van Orten-Luiten, Nicole M. de Roos, Soumia Majait, Ben J.M. Witteman, Renger F. Witkamp

    Background: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. Its pathophysiology is diverse and variable, involving disturbed gut–brain interactions, altered motility and secretion, visceral hypersensitivity, increased intestinal permeability, immune activation, and changes in gut microbiota. Complaints experienced by patients suffering from IBS and its co-morbidities strongly impair quality of life (QoL), and available treatments are often unsatisfactory. Anecdotal reports and preclinical data suggest that the endocannabinoid system and functionally related mechanisms could offer treatment targets. Cannabidiol (CBD) is a candidate agent of interest with a broad molecular target profile and the absence of psychoactive properties. Materials and Methods: In 32 female IBS patients, we explored the effect of a chewing gum formulation containing 50 mg CBD on abdominal pain and perceived well-being in a randomized, double-blinded, placebo-controlled cross-over trial. Chewing gums were used on-demand guided by pain symptoms with a maximum of six per day. Pain intensity was assessed by a visual analogue scale (scale 0.0–10.0), and QoL was evaluated with the IBS-36 questionnaire. Results: There was no statistically significant difference in pain scores between CBD and placebo at a group level. Subgroup and individual analyses showed a highly variable picture. No indications were found for symptom-driven intake, which also remained lower than expected overall. Conclusions: With the current design, based on the assumption that IBS patients would adjust their intake to their perceived symptom relief, no differences at the group level were found between CBD and placebo gum in pain scores and the number of gums used. The low use of the gums also indicates that the benefits experienced by these patients generally did not outweigh practical disadvantages such as prolonged chewing throughout the day. The very high intra- and inter-individual variation in IBS symptoms warrant future trials that are more personalized, for example by applying an N-of-1 (rotating) design with individualized dose titration.


  • Open Access

    The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses

    by Paulien Vinke, Evertine Wesselink, Wout van Orten-Luiten, Klaske van Norren

    Long-term use of proton pump inhibitors (PPIs) is common in patients with muscle wasting-related chronic diseases. We explored the hypothesis that the use of PPIs may contribute to a reduction in muscle mass and function in these patients. Literature indicates that a PPI-induced reduction in acidity of the gastrointestinal tract can decrease the absorption of, amongst others, magnesium. Low levels of magnesium are associated with impaired muscle function. This unwanted side-effect of PPIs on muscle function has been described in different disease backgrounds. Furthermore, magnesium is necessary for activation of vitamin D. Low vitamin D and magnesium levels together can lead to increased inflammation involved in muscle wasting. In addition, PPI use has been described to alter the microbiota’s composition in the gut, which might lead to increased inflammation. However, PPIs are often provided together with nonsteroidal anti-inflammatory drugs (NSAIDs), which are anti-inflammatory. In the presence of obesity, additional mechanisms could further contribute to muscle alterations. In conclusion, use of PPIs has been reported to contribute to muscle function loss. Whether this will add to the risk factor for development of muscle function loss in patients with chronic disease needs further investigation.


  • Drug use is associated with lower plasma magnesium levels in geriatric outpatients; possible clinical relevance

    by A.C.B. van Orten-Luiten, A. Janse, E. Verspoor, E.M. Brouwer-Brolsma, R.F. Witkamp


  • PT01.6: Drug Use and Serum Magnesium in Dutch Geriatric Outpatients

    by A.C.B. van Orten-Luiten, A. Janse, E.M. Brouwer-Brolsma, R.F. Witkamp

  • Open Access

    Public health relevance of drug–nutrition interactions

    by Szabolcs Péter, Gerjan Navis, Martin H. de Borst, Clemens von Schacky, Anne Claire B. van Orten-Luiten, Alexandra Zhernakova, Renger F. Witkamp, André Janse, Peter Weber, Stephan J. L. Bakker, et al.

    The public health relevance of drug–nutrition interactions is currently highly undervalued and overlooked. This is particularly the case for elderly persons where multi-morbidity and consequently polypharmacy is very common. Vitamins and other micronutrients have central functions in metabolism, and their interactions with drugs may result in clinically relevant physiological impairments but possibly also in positive effects. On 12 April 2016, the University Medical Center Groningen (The Netherlands), as part of its Healthy Ageing program, organized a workshop on the public health relevance of drug–nutrient interactions. In this meeting, experts in the field presented results from recent studies on interactions between pharmaceuticals and nutrients, and discussed the role of nutrition for elderly, focusing on those persons receiving pharmaceutical treatment. This paper summarizes the proceedings of the symposium and provides an outlook for future research needs and public health measures. Since food, pharma and health are closely interconnected domains, awareness is needed in the medical community about the potential relevance of drug–nutrition interactions. Experts and stakeholders should advocate for the integration of drug–nutrition evaluations in the drug development process. Strategies for the individual patients should be developed, by installing drug review protocols, screening for malnutrition and integrating this topic into the general medical advice.


  • Drug-Nutrition Interactions in Older People

    by A.C. van Orten-Luiten, A. Janse, R. Witkamp

  • Open Access

    Vitamin D deficiency as adverse drug reaction? A cross-sectional study in Dutch geriatric outpatients

    by A. C. B. van Orten-Luiten, A. Janse, R. A. M. Dhonukshe-Rutten, R. F. Witkamp

    Purpose Adverse drug reactions as well as vitamin D deficiency are issues of public health concern in older people. However, relatively little is known about the impact of drug use on vitamin D status. Our primary aim is to explore associations between drug use and vitamin D status in older people. Furthermore, prevalences of drug use and vitamin D deficiency are estimated. Methods In a population of 873 community-dwelling Dutch geriatric outpatients, we explored the cross-sectional relationships of polypharmacy (≥5 medications concomitantly used), severe polypharmacy (≥10 medications), and use of twenty-one specific drug groups, with serum 25-hydroxyvitamin D (25(OH)D) by analysis of covariance. Results Overall prevalence of polypharmacy was 65 %, of severe polypharmacy 22 %. Depending on the cut-off value, prevalence of vitamin D deficiency was 49 % (<50 nmol/l) or 77 % (<75 nmol/l). Of the patients using a vitamin D supplement, 17 % (<50 nmol/l) or 49 % (<75 nmol/l) were still deficient. In non-users of supplemental vitamin D, after adjustment for age and gender, negative associations were found for severe polypharmacy, metformin, sulphonamides and urea derivatives (SUDs), vitamin K antagonists, cardiac glycosides, loop diuretics, potassium-sparing diuretics, ACE inhibitors, and serotonin reuptake inhibitors; for non-selective monoamine reuptake inhibitors (NSMRIs) the association was positive. The most extreme impacts of drug use on adjusted mean 25(OH)D were −19 nmol/l for SUDs and +18 nmol/l for NSMRIs. Conclusion Drug use should be considered a risk factor for vitamin D deficiency amongst geriatric outpatients.


  • Open Access

    Dietary supplement use and colorectal cancer risk: A systematic review and meta‐analyses of prospective cohort studies

    by Renate C. Heine‐Bröring, Renate M. Winkels, Jacoba M.S. Renkema, Lea Kragt, Anne‐Claire B. van Orten‐Luiten, Ettje F. Tigchelaar, Doris S.M. Chan, Teresa Norat, Ellen Kampman

    Use of dietary supplements is rising in countries where colorectal cancer is prevalent. We conducted a systematic literature review and meta‐analyses of prospective cohort studies on dietary supplement use and colorectal cancer risk. We identified relevant studies in Medline, Embase and Cochrane up to January 2013. Original and peer‐reviewed papers on dietary supplement use and colorectal cancer, colon cancer, or rectal cancer incidence were included. “Use‐no use”(U‐NU), “highest‐lowest”(H‐L) and “dose‐response”(DR) meta‐analyses were performed. Random‐effects models were used to estimate summary estimates. In total, 24 papers were included in the meta‐analyses. We observed inverse associations for colorectal cancer risk and multivitamin (U‐NU: RR = 0.92; 95% CI: 0.87,0.97) and calcium supplements (U‐NU: RR = 0.86; 95% CI: 0.79,0.95; H‐L: RR = 0.80; 95% CI: 0.70,0.92; DR: for an increase of 100 mg/day, RR = 0.96; 95% CI: 0.94,0.99). Inconsistent associations were found for colon cancer risk and supplemental vitamin A and vitamin C, and for colorectal cancer risk and supplemental vitamin D, vitamin E, garlic and folic acid. Meta‐analyses of observational studies suggest a beneficial role for multivitamins and calcium supplements on colorectal cancer risk, while the association with other supplements and colorectal cancer risk is inconsistent. Residual confounding of lifestyle factors might be present. Before recommendations can be made, an extensive assessment of dietary supplement use and a better understanding of underlying mechanisms is needed.